{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:07:02Z","timestamp":1761844022005},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,7,2]],"date-time":"2010-07-02T00:00:00Z","timestamp":1278028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Medical Primatology"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> The best current animal model for HIV infection and evaluation of antiviral compounds is the Simian\u2013human immunodeficiency virus (SHIV)\/macaque system. There are multiple recombinant SHIVs available, but these viruses have limitations in evaluating combination drug strategies for prevention. Drug combinations that target reverse transcriptase (RT, either nRTI or nnRTI) and envelope (entry or fusion inhibitors) have to be tested separately, which does not permit the assessment of additive, synergistic, or antagonistic effects of ARV combinations. We describe construction of a dual SHIV containing both HIV RT and a CCR5\u2010specific HIV envelope gene in a simian immunodeficiency virus backbone.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> The RT Env SHIV molecular clone was constructed using RT SHIV and SHIV162p3 sequences as templates to generate RT Env SHIV. RT Env SHIV was expanded <jats:italic>in vitro<\/jats:italic> in CD8\u2010depleted macaque peripheral blood mononuclear cells (PBMC). Recombinant virus was used to infect a rhesus macaque (4.3\u2003\u00d7\u200310<jats:sup>4<\/jats:sup> tissue culture infectious dose [TCID<jats:sub>50<\/jats:sub>], intravenously [IV]). A second passage in a macaque by IV transfer of 10\u2003ml of blood obtained from the first infection was also done. The <jats:italic>in vivo<\/jats:italic> adapted virus stock from these macaques was used to produce high titer stocks <jats:italic>in vitro<\/jats:italic> and used to rectally infect an additional macaque.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Peak viral load reached 6\u2003\u00d7\u200310<jats:sup>5<\/jats:sup> vRNA copies\/ml in plasma in both IV\u2010exposed macaques and remained detectable in the one animal for 16\u2003weeks after infection. A viral stock (1.68\u2003\u00d7\u200310<jats:sup>4<\/jats:sup> TCID<jats:sub>50<\/jats:sub>) derived from the second macaque passage has been produced in CD8\u2010depleted rhesus PBMC and was successfully used to demonstrate mucosal transmission. The resulting RT Env SHIV retained the sensitivity to HIV RT and entry inhibitors of its parental viruses.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The objective of this study was to develop and characterize a SHIV recombinant virus for evaluating the efficacy of ART and microbicide products that target both HIV RT and\/or Env\u2010mediated entry. RT Env SHIV can productively infect macaques by both the IV and mucosal route, making it a valuable tool for transmission studies.<\/jats:p>","DOI":"10.1111\/j.1600-0684.2010.00434.x","type":"journal-article","created":{"date-parts":[[2010,7,6]],"date-time":"2010-07-06T20:21:41Z","timestamp":1278447701000},"page":"213-223","source":"Crossref","is-referenced-by-count":11,"title":["Generation of a dual RT Env SHIV that is infectious in rhesus macaques"],"prefix":"10.1111","volume":"39","author":[{"given":"James M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Dauner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hendry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Ellenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sal","family":"Butera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron A.","family":"Otten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.18843-0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.24.13553-13561.2004"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.1.97"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199705010-00001"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.7.9.1419"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.10.013"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70254-8"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050028"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160355"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812587106"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.2.989-998.2003"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-5-94"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1128\/jvi.71.5.4016-4023.1997","article-title":"Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian\/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS","volume":"71","author":"Joag SV","year":"1997","journal-title":"J Virol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200822030-00003"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0684.2006.00169.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00424-07"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328322402e"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099288"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.5.3045-3050.1996"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.16.7490"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328334fe70"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/426452"},{"key":"e_1_2_6_24_2","first-page":"471","article-title":"Integrase inhibitors for the treatment of HIV infection","volume":"11","author":"Pace P","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.01.002"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01073-09"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31817dfdb8"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0684.2009.00354.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.10.6922-6928.1996"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-009-9082-7"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2008.0184"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02660-07"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2636"},{"key":"e_1_2_6_34_2","first-page":"385","volume-title":"Medicinal Protein Engineering, Ch 16","author":"Smith JM","year":"2008"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2013"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/507306"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0684.1999.tb00265.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.18.8210"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.07.008"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04055"}],"container-title":["Journal of Medical Primatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0684.2010.00434.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0684.2010.00434.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T06:11:25Z","timestamp":1697436685000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0684.2010.00434.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,2]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1600-0684.2010.00434.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0684.2010.00434.x","archive":["Portico"],"relation":{},"ISSN":["0047-2565","1600-0684"],"issn-type":[{"value":"0047-2565","type":"print"},{"value":"1600-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,2]]}}}